Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95999
UPID:
BCL10_HUMAN
Alternative names:
B-cell CLL/lymphoma 10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; CED-3/ICH-1 prodomain homologous E10-like regulator; Cellular homolog of vCARMEN; Cellular-E10; Mammalian CARD-containing adapter molecule E10
Alternative UPACC:
O95999; Q5VUF1
Background:
B-cell lymphoma/leukemia 10 (BCL10) is pivotal in immune signaling, bridging CARD domain-containing proteins to immune activation. It plays a crucial role in both adaptive and innate immunity, activating NF-kappa-B and MAP kinase pathways, stimulating pro-inflammatory cytokine and chemokine expression. BCL10's involvement in forming the CBM complex upon activation by CARD domain-containing proteins underscores its significance in immune response regulation.
Therapeutic significance:
BCL10's association with Immunodeficiency 37 and mucosa-associated lymphoid type lymphoma highlights its therapeutic potential. Understanding BCL10's role could pave the way for innovative treatments targeting immune signaling pathways, offering hope for patients with these conditions.